This vaccine mostly induces expansion of CD4+ T cells in the spleen and lymph nodes and elicits robust Kras‐specific T cell responses that inhibit tumor growth.[31, 32] To test the ability of let‐7b to potentiate the efficacy of KVax, we established lung tumors via tail vein injection of LKR13 cells. Here, KRAS is linked to neoplasm.